Skip to main content
. 2022 May 23;10(5):828. doi: 10.3390/vaccines10050828

Figure 2.

Figure 2

Vaccine formulation. (a) Schematic representation of the Tag/Catcher-AP205 technology used to create the cVLP:IL-1β vaccines. Genetic fusion of the split-protein Catcher to the AP205 capsid protein (total of 180 subunits per cVLP) allows for high-density, unidirectional display of IL-1β antigens fused to the corresponding binding Tag. (b) M: marker, lane 1: cVLP:IL-1β after O/N incubation at 4 °C (48 kDa), lane 2: cVLP:IL-1β after O/N incubation at 4 °C (48 kDa) + spin test, lane 3: cVLP:IL-1β Q15G after O/N incubation at 4 °C (48 kDa), lane 4: cVLP:IL-1β Q15G after O/N incubation at 4 °C (48 kDa) + spin test. Excess IL-1β-Tag antigen (21 kDa) and unconjugated cVLP subunits (27 kDa) were present in all the coupling reactions.